DYNE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.68 USD | +0.10% |
|
-0.97% | +92.33% |
| May. 02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 14.06M | Capitalization | 2.24B |
|---|---|---|---|---|---|
| Net income 2024 * | -259M | Net income 2025 * | -292M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 191M | Net cash position 2025 * | 301M | EV / Sales 2025 * | 138 x |
| P/E ratio 2024 * |
-8.27
x | P/E ratio 2025 * |
-7.83
x | Employees | 143 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -2.29% | ||
| 1 week | +1.34% | ||
| Current month | +1.34% | ||
| 1 month | -2.99% | ||
| 3 months | +19.64% | ||
| 6 months | +174.33% | ||
| Current year | +92.86% |
1 week
24.79
27.31
1 month
23.1127.80
Current year
12.3330.27
1 year
6.4030.27
3 years
4.3030.27
5 years
4.3032.32
10 years
4.3032.32
| Managers | Title | Age | Since |
|---|---|---|---|
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Rick Scalzo
DFI | Director of Finance/CFO | 38 | 19-11-30 |
John Najim
CTO | Chief Tech/Sci/R&D Officer | 48 | 19-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Edward Hurwitz
BRD | Director/Board Member | 60 | 18-10-31 |
David Lubner
BRD | Director/Board Member | 60 | 20-02-29 |
Dirk Kersten
BRD | Director/Board Member | 49 | 18-10-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 25.59 | -0.23% | 288 270 |
| 24-05-07 | 25.65 | -2.29% | 496,815 |
| 24-05-06 | 26.25 | +0.65% | 646,639 |
| 24-05-03 | 26.08 | +0.31% | 761,928 |
| 24-05-02 | 26 | +0.66% | 935,703 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotes
Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Calendar
2024-05-22
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
25.65
USD
Average target price
37.8
USD
Spread / Average Target
+47.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +92.86% | 2.24B | |
| +21.74% | 46.4B | |
| -0.97% | 41.75B | |
| +47.07% | 41.37B | |
| -3.52% | 29.71B | |
| +11.12% | 26.01B | |
| -19.37% | 19.52B | |
| +31.18% | 12.43B | |
| -0.04% | 12.13B | |
| +0.39% | 12.18B |
- Stock Market
- Equities
- DYN Stock